Moderna became the fourth company to sell COVID-19 vaccines in South Korea after AstraZeneca PLC, Pfizer-BioNTech and Johnson & Johnson, according to the Ministry of Food and Drug Safety. GC Pharma, a biopharmaceutical company in South Korea, would import Moderna's vaccine on the condition that it would submit the final results of clinical trials later.
Experts determined that the prevention effect of Moderna's vaccine was 94.1 percent in clinical trials, while abnormalities were acceptable. South Korea aims to purchase foreign vaccines for 79 million people, which are enough to vaccinate the entire population of 51 million.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.